Drug
Ktn3379
Ktn3379: highest development phase Phase 1, developed by Celldex Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Celldex Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| KTN3379 NCT02473731 | Phase 1 | Squamous Cell Carcinoma of the Head and Neck |
| KTN3379 NCT02014909 | Phase 1 | Advanced Cancer |
| KTN3379 NCT02456701 | Phase 1 | Thyroid Cancer |
Latest
No recent events.
Follow Ktn3379 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.